Dyadic International (NASDAQ:DYAI) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Dyadic International, Inc. (NASDAQ:DYAI)’s stock price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.66 and traded as low as $1.52. Dyadic International shares last traded at $1.54, with a volume of 25,519 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a research report on Thursday, November 14th.

Dyadic International Stock Performance

The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. The firm has a market cap of $43.50 million, a P/E ratio of -6.39 and a beta of 0.89. The company’s 50 day moving average is $1.67 and its 200 day moving average is $1.39.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The company had revenue of $1.96 million for the quarter, compared to the consensus estimate of $1.05 million. During the same quarter last year, the business posted ($0.06) EPS. As a group, equities analysts predict that Dyadic International, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently bought a new position in Dyadic International stock. Inlet Private Wealth LLC purchased a new stake in Dyadic International, Inc. (NASDAQ:DYAI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the biotechnology company’s stock, valued at approximately $52,000. Inlet Private Wealth LLC owned 0.10% of Dyadic International at the end of the most recent quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.